CANCELLED: NorTrials gastrointestinal research event
6 October 2025, 19:00 - 21:00 GMT
Seminar
Come meet a united coalition from Norway’s healthcare system and healthcare industry to discuss Norway’s ambitious strategic plan aimed at strengthening Norway’s position as a leading country of excellence in the field of clinical trials.
Programme elements
We regret to inform you that the event has been cancelled.
If you are interested in alternative formats for discussing the latest in gastrointestinal research and collaboration opportunities within NorTrials, please reach out to the NorTrials center for gastrointestinal diseases: Gastrointestinal - NorTrials.
The Norwegian Ministry of health has launched an ambitious strategic plan to strengthen Norway as a country of excellence for clinical trials. In collaboration with the industry, NorTrials as a national entry point for global companies wishing to conduct clinical trials in Norway, was established in 2022.
Norway's strengths within clinical trials
- Access to world-class clinical trial units and internationally renowned clinicians and researchers
- One of the extensive collections of health registries in the world
- Established links between health data and biobanks
- National infrastructure for precision diagnostics and advanced molecular diagnostics implemented as part of the public health care services
- On-going public-private collaborations for development of healthcare services
A well-structured specialist care system and a population with a high willingness to partake in clinical trialsRepresentatives from the Embassy, the healthcare industry, key-opinion leaders from the clinical side, Innovation Norway and NorTrials will meet and discuss how choosing Norway as a preferred clinical trials hosting country will strengthen the pipeline execution and advance strategic clinical trial development.
We invite you to join us and hear from our experts as they present the clinical trials strategy of the future.
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.